MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 564554 | Name: Nimbolide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nimbolide is a natural inhibitor of pancreatic cancer growth and metastasis through ROS-mediated apoptosis. It inhibits epithelial-to-mesenchymal transition.

Chemical Structure

Nimbolide
CAS#25990-37-8

Theoretical Analysis

MedKoo Cat#: 564554

Name: Nimbolide

CAS#: 25990-37-8

Chemical Formula: C27H30O7

Exact Mass: 466.1992

Molecular Weight: 466.53

Elemental Analysis: C, 69.51; H, 6.48; O, 24.01

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 Weeks
25mg USD 1,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Nimbolide
IUPAC/Chemical Name
8(R)-(3-Furanyl)-2aR,5aR,6S,6aR,8R,9,9aR,10aS,10bR,10cR-decahydro-2a,5a,6a,7-tetramethyl-2,5-dioxo-2H,5H-cyclopenta[d']naphtho[1,8-bc:2,3-b']difuran-6-acetic acid, methyl ester
InChi Key
JZIQWNPPBKFOPT-LSYMHUITSA-N
InChi Code
InChI=1S/C27H30O7/c1-13-15(14-7-9-32-12-14)10-16-20(13)27(4)17(11-19(29)31-5)26(3)18(28)6-8-25(2)22(26)21(23(27)33-16)34-24(25)30/h6-9,12,15-17,21-23H,10-11H2,1-5H3/t15-,16-,17-,21-,22+,23-,25-,26+,27-/m1/s1
SMILES Code
CC1=C2[C@H](O[C@@H]3[C@H](O4)[C@@H]5[C@@](C(C=C[C@@]5(C)C4=O)=O)(C)[C@@H](CC(OC)=O)[C@]23C)C[C@H]1C6=COC=C6
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Nimbolide induces apoptosis through inactivation of NF-κB. Nimbolide inhibits CDK4/CDK6 kinase activity. Nimbolide suppresses the NF-κB, Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways.
In vitro activity:
Nimbolide impairs breast cancer cell proliferation in-part by disrupting RNF114-substrate recognition, leading to inhibition of ubiquitination and degradation of tumor suppressors such as p21, resulting in their rapid stabilization. This study further demonstrates that nimbolide can be harnessed to recruit RNF114 as an E3 ligase in targeted protein degradation applications and show that synthetically simpler scaffolds are also capable of accessing this unique reactive site. Reference: Nat Chem Biol. 2019 Jul;15(7):747-755. https://pubmed.ncbi.nlm.nih.gov/31209351/
In vivo activity:
Lastly, intraperitoneal administration of nimbolide in WM tumor xenografted mice, significantly reduced tumor growth and IgM secretion in vivo, while modulating the expression of several proteins as seen on immunohistochemistry. Reference: Blood Cancer J. 2014 Nov 7;4(11):e260. https://pubmed.ncbi.nlm.nih.gov/25382610/
Solvent mg/mL mM comments
Solubility
DMF 12.0 25.72
DMF:PBS (pH 7.2) (1:1) 0.5 1.07
DMSO 35.9 76.92
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 466.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Tong B, Spradlin JN, Novaes LFT, Zhang E, Hu X, Moeller M, Brittain SM, McGregor LM, McKenna JM, Tallarico JA, Schirle M, Maimone TJ, Nomura DK. A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL. ACS Chem Biol. 2020 Jul 17;15(7):1788-1794. doi: 10.1021/acschembio.0c00348. Epub 2020 Jun 25. PMID: 32568522; PMCID: PMC7891886. 2. Spradlin JN, Hu X, Ward CC, Brittain SM, Jones MD, Ou L, To M, Proudfoot A, Ornelas E, Woldegiorgis M, Olzmann JA, Bussiere DE, Thomas JR, Tallarico JA, McKenna JM, Schirle M, Maimone TJ, Nomura DK. Harnessing the anti-cancer natural product nimbolide for targeted protein degradation. Nat Chem Biol. 2019 Jul;15(7):747-755. doi: 10.1038/s41589-019-0304-8. Epub 2019 Jun 17. PMID: 31209351; PMCID: PMC6592714. 3. Israr M, Naseem N, Akhtar T, Aftab U, Zafar MS, Faheem MA, Shahzad M. Nimbolide attenuates complete Freund's adjuvant induced arthritis through expression regulation of toll-like receptors signaling pathway. Phytother Res. 2023 Mar;37(3):903-912. doi: 10.1002/ptr.7672. Epub 2022 Nov 27. PMID: 36437579. 4. Chitta K, Paulus A, Caulfield TR, Akhtar S, Blake MK, Ailawadhi S, Knight J, Heckman MG, Pinkerton A, Chanan-Khan A. Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia. Blood Cancer J. 2014 Nov 7;4(11):e260. doi: 10.1038/bcj.2014.74. PMID: 25382610; PMCID: PMC5424099.
In vitro protocol:
1. Tong B, Spradlin JN, Novaes LFT, Zhang E, Hu X, Moeller M, Brittain SM, McGregor LM, McKenna JM, Tallarico JA, Schirle M, Maimone TJ, Nomura DK. A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL. ACS Chem Biol. 2020 Jul 17;15(7):1788-1794. doi: 10.1021/acschembio.0c00348. Epub 2020 Jun 25. PMID: 32568522; PMCID: PMC7891886. 2. Spradlin JN, Hu X, Ward CC, Brittain SM, Jones MD, Ou L, To M, Proudfoot A, Ornelas E, Woldegiorgis M, Olzmann JA, Bussiere DE, Thomas JR, Tallarico JA, McKenna JM, Schirle M, Maimone TJ, Nomura DK. Harnessing the anti-cancer natural product nimbolide for targeted protein degradation. Nat Chem Biol. 2019 Jul;15(7):747-755. doi: 10.1038/s41589-019-0304-8. Epub 2019 Jun 17. PMID: 31209351; PMCID: PMC6592714.
In vivo protocol:
1. Israr M, Naseem N, Akhtar T, Aftab U, Zafar MS, Faheem MA, Shahzad M. Nimbolide attenuates complete Freund's adjuvant induced arthritis through expression regulation of toll-like receptors signaling pathway. Phytother Res. 2023 Mar;37(3):903-912. doi: 10.1002/ptr.7672. Epub 2022 Nov 27. PMID: 36437579. 2. Chitta K, Paulus A, Caulfield TR, Akhtar S, Blake MK, Ailawadhi S, Knight J, Heckman MG, Pinkerton A, Chanan-Khan A. Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia. Blood Cancer J. 2014 Nov 7;4(11):e260. doi: 10.1038/bcj.2014.74. PMID: 25382610; PMCID: PMC5424099.
1: Sophia J, Kowshik J, Dwivedi A, Bhutia SK, Manavathi B, Mishra R, Nagini S. Nimbolide, a neem limonoid inhibits cytoprotective autophagy to activate apoptosis via modulation of the PI3K/Akt/GSK-3β signalling pathway in oral cancer. Cell Death Dis. 2018 Oct 23;9(11):1087. doi: 10.1038/s41419-018-1126-4. PubMed PMID: 30352996; PubMed Central PMCID: PMC6199248. 2: Diddi S, Bale S, Pulivendala G, Godugu C. Nimbolide ameliorates fibrosis and inflammation in experimental murine model of bleomycin-induced scleroderma. Inflammopharmacology. 2018 Sep 14. doi: 10.1007/s10787-018-0527-4. [Epub ahead of print] PubMed PMID: 30218238. 3: Wang L, Phan DK, Syn N, Xiang X, Song H, Thuya WL, Yang S, Wong AL, Kumar AP, Yong WP, Sethi G, Ho PC, Goh BC. A Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Nimbolide in Mouse Serum: Application to a Preclinical Pharmacokinetics Study. Pharmaceutics. 2018 Aug 8;10(3). pii: E123. doi: 10.3390/pharmaceutics10030123. PubMed PMID: 30096831; PubMed Central PMCID: PMC6161292. 4: Hsueh KC, Lin CL, Tung JN, Yang SF, Hsieh YH. Nimbolide induced apoptosis by activating ERK-mediated inhibition of c-IAP1 expression in human hepatocellular carcinoma cells. Environ Toxicol. 2018 Sep;33(9):913-922. doi: 10.1002/tox.22576. Epub 2018 Jul 2. PubMed PMID: 29962003. 5: Baira SM, Khurana A, Somagoni J, Srinivas R, Godugu C, Talluri MVNK. First report on the pharmacokinetic profile of nimbolide, a novel anticancer agent in oral and intravenous administrated rats by LC/MS method. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 15;1092:191-198. doi: 10.1016/j.jchromb.2018.06.002. Epub 2018 Jun 2. PubMed PMID: 29908468. 6: Pooladanda V, Bandi S, Mondi SR, Gottumukkala KM, Godugu C. Nimbolide epigenetically regulates autophagy and apoptosis in breast cancer. Toxicol In Vitro. 2018 Sep;51:114-128. doi: 10.1016/j.tiv.2018.05.010. Epub 2018 May 17. PubMed PMID: 29778718. 7: Patel MJ, Tripathy S, Mukhopadhyay KD, Wangjam T, Cabang AB, Morris J, Wargovich MJ. A supercritical CO(2) extract of neem leaf (A. indica) and its bioactive liminoid, nimbolide, suppresses colon cancer in preclinical models by modulating pro-inflammatory pathways. Mol Carcinog. 2018 Sep;57(9):1156-1165. doi: 10.1002/mc.22832. Epub 2018 May 8. PubMed PMID: 29697164. 8: Ahmad MF, Ansari MO, Jameel S, Wani AL, Parveen N, Siddique HR, Shadab GGHA. Protective role of nimbolide against chemotherapeutic drug hydroxyurea induced genetic and oxidative damage in an animal model. Environ Toxicol Pharmacol. 2018 Jun;60:91-99. doi: 10.1016/j.etap.2018.04.006. Epub 2018 Apr 12. PubMed PMID: 29679812. 9: Odoh UE, Uzor PF, Eze CL, Akunne TC, Onyegbulam CM, Osadebe PO. Medicinal plants used by the people of Nsukka Local Government Area, south-eastern Nigeria for the treatment of malaria: An ethnobotanical survey. J Ethnopharmacol. 2018 May 23;218:1-15. doi: 10.1016/j.jep.2018.02.034. PubMed PMID: 29477369. 10: Sengupta P, Raman S, Chowdhury R, Lohitesh K, Saini H, Mukherjee S, Paul A. Evaluation of Apoptosis and Autophagy Inducing Potential of Berberis aristata, Azadirachta indica, and Their Synergistic Combinations in Parental and Resistant Human Osteosarcoma Cells. Front Oncol. 2017 Dec 11;7:296. doi: 10.3389/fonc.2017.00296. eCollection 2017. PubMed PMID: 29312880; PubMed Central PMCID: PMC5732233. 11: Vora J, Patel S, Sinha S, Sharma S, Srivastava A, Chhabria M, Shrivastava N. Molecular docking, QSAR and ADMET based mining of natural compounds against prime targets of HIV. J Biomol Struct Dyn. 2018 Jan 7:1-16. doi: 10.1080/07391102.2017.1420489. [Epub ahead of print] PubMed PMID: 29268664. 12: Alshammari GM, Balakrishnan A, Chinnasamy T. Nimbolide attenuate the lipid accumulation, oxidative stress and antioxidant in primary hepatocytes. Mol Biol Rep. 2017 Dec;44(6):463-474. doi: 10.1007/s11033-017-4132-1. Epub 2017 Nov 28. PubMed PMID: 29185131. 13: Kumar S, Inigo JR, Kumar R, Chaudhary AK, O'Malley J, Balachandar S, Wang J, Attwood K, Yadav N, Hochwald S, Wang X, Chandra D. Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. Cancer Lett. 2018 Jan 28;413:82-93. doi: 10.1016/j.canlet.2017.10.029. Epub 2017 Oct 26. PubMed PMID: 29107110; PubMed Central PMCID: PMC5706561. 14: Gupta SC, Prasad S, Tyagi AK, Kunnumakkara AB, Aggarwal BB. Neem (Azadirachta indica): An indian traditional panacea with modern molecular basis. Phytomedicine. 2017 Oct 15;34:14-20. doi: 10.1016/j.phymed.2017.07.001. Epub 2017 Jul 3. Review. PubMed PMID: 28899496. 15: Siva B, Devi A, Venkanna A, Poornima B, Sukumar G, Reddy SD, Vijaya M, Ummanni R, Babu KS. "Click" reaction based synthesis of nimbolide derivatives and study of their insect antifeedant activity against Spodoptera litura Larvae. Fitoterapia. 2017 Nov;123:1-8. doi: 10.1016/j.fitote.2017.09.005. Epub 2017 Sep 6. PubMed PMID: 28888965. 16: Kashif M, Hwang Y, Hong G, Kim G. In vitro comparative cytotoxic effect of Nimbolide: A limonoid from Azadirachta indica (Neem tree) on cancer cell lines and normal cell lines through MTT assay. Pak J Pharm Sci. 2017 May;30(3(Suppl.)):967-973. PubMed PMID: 28655693. 17: Lin H, Qiu S, Xie L, Liu C, Sun S. Nimbolide suppresses non-small cell lung cancer cell invasion and migration via manipulation of DUSP4 expression and ERK1/2 signaling. Biomed Pharmacother. 2017 Aug;92:340-346. doi: 10.1016/j.biopha.2017.05.072. Epub 2017 May 26. PubMed PMID: 28554129. 18: Kowshik J, Mishra R, Sophia J, Rautray S, Anbarasu K, Reddy GD, Dixit M, Mahalingam S, Nagini S. Nimbolide upregulates RECK by targeting miR-21 and HIF-1α in cell lines and in a hamster oral carcinogenesis model. Sci Rep. 2017 May 17;7(1):2045. doi: 10.1038/s41598-017-01960-5. PubMed PMID: 28515436; PubMed Central PMCID: PMC5435722. 19: Wen Z, Mei B, Li H, Dou Y, Tian X, Shen M, Chen G. P2X7 Participates in Intracerebral Hemorrhage-Induced Secondary Brain Injury in Rats via MAPKs Signaling Pathways. Neurochem Res. 2017 Aug;42(8):2372-2383. doi: 10.1007/s11064-017-2257-1. Epub 2017 May 9. PubMed PMID: 28488233. 20: Chien SY, Hsu CH, Lin CC, Chuang YC, Lo YS, Hsi YT, Hsieh MJ, Chen MK. Nimbolide induces apoptosis in human nasopharyngeal cancer cells. Environ Toxicol. 2017 Aug;32(8):2085-2092. doi: 10.1002/tox.22423. Epub 2017 Apr 6. PubMed PMID: 28383207.

View History

Diclofenac etalhyaluronate

Diclofenac etalhyaluronate